SCHEMBL17260466

SCHEMBL17260466

CC(=O)Nc1nc2c(c(=O)[nH]1)N=C[N]2

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GDA Q9Y2T3 1/20 0.47
FGFR1 P11362 6/20 0.45
FGFR2 P21802 6/20 0.45
ALDH1A1 P00352 3/20 0.45
ALOX15 P16050 2/20 0.45
POLB P06746 2/20 0.45
KDM4E B2RXH2 3/20 0.45
GAA P10253 1/20 0.45
LMNA P02545 1/20 0.44
ADORA3 P0DMS8 2/20 0.43
TDP1 Q9NUW8 1/20 0.42
FGFR3 P22607 3/20 0.39
KMT2A Q03164 2/20 0.37
MEN1 O00255 1/20 0.36
TSHR P16473 1/20 0.36
HSD17B10 Q99714 1/20 0.35
MAPT P10636 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4337068 0.84 PAX3 (0.39) GDAFGFR1FGFR2ALDH1A1ALOX15
SCHEMBL25324519 0.80 RAB9A (0.51) POLBKDM4ELMNAADORA3KMT2A
SCHEMBL17260490 0.74 POLB (0.35) FGFR1FGFR2ALDH1A1ALOX15POLB
SCHEMBL8781880 0.69 CYP1A2 (0.40) ALDH1A1POLBKDM4EADORA3KMT2A
SCHEMBL7807597 0.68 CYP1A2 (0.39) ALDH1A1POLBADORA3KMT2A
SCHEMBL24802600 0.67 ADORA3 (0.56) GDAFGFR1FGFR2ALDH1A1ALOX15
SCHEMBL16639430 0.65 ADORA3 (0.54) GDAFGFR1FGFR2ALDH1A1ALOX15
SCHEMBL219477 0.65 GDA (0.62) GDAFGFR1FGFR2ALDH1A1ALOX15
SCHEMBL29123832 0.65 KDM4E (0.68) GDAFGFR1FGFR2ALDH1A1ALOX15
SCHEMBL28520039 0.65 DYRK1A (0.53) GDAFGFR1FGFR2ALDH1A1ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3143038-A1 PEPTIDE NUCLEIC ACID MONOMERS AND OLIGOMERS Ugisense AG (DE) 2017-03-22 EP claimed
WO-2015172889-A1 PEPTIDE NUCLEIC ACID MONOMERS AND OLIGOMERS UGICHEM GMBH (AT) 2015-11-19 WO claimed
US-20230257413-A1 ARTIFICIAL NUCLEIC ACID, METHOD FOR PRODUCING SAME, AND USE THEREOF RIKEN GENESIS CO., LTD. (JP) 2023-08-17 US disclosed
EP-4219517-A1 NOVEL ARTIFICIAL NUCLEIC ACID, METHOD FOR PRODUCING SAME, AND USE THEREOF Riken Genesis Co., Ltd. (JP) 2023-08-02 EP disclosed
WO-2023127857-A1 NOVEL ARTIFICIAL NUCLEIC ACID, METHOD FOR PRODUCING SAME, AND USE OF SAME 株式会社理研ジェネシス 2023-07-06 WO disclosed
CN-116322706-A Novel artificial nucleic acid, method for producing same, and use thereof 株式会社理真思 2023-06-23 CN disclosed
CN-113646007-A Novel artificial nucleic acid, method for producing same, and use thereof 希森美康株式会社 2021-11-12 CN disclosed
CN-1045089-C 2- (2-amino-1, 6-dihydro-6-oxo-purin-9-yl) methoxy-1, 3-propanediol derivatives HOFFMANN LA ROCHE (CH) 1999-09-15 CN disclosed
CN-1122804-A 2- (2-amino-1, 6-dihydro-6-oxo-purin-9-yl) methoxy-1, 3-propanediol derivatives HOFFMANN LA ROCHE (CH) 1996-05-22 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230257413-A1 ARTIFICIAL NUCLEIC ACID, METHOD FOR PRODUCING SAME, AND USE THEREOF NSUN2, NSUN3, POLRMT GDA 662/4885FGFR1 1100/4885FGFR2 1384/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.